Throughout the last three months, 18 analysts have evaluated Intra-Cellular Therapies ITCI, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 12 | 5 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 7 | 2 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $91.94, a high estimate of $120.00, and a low estimate of $77.00. Marking an increase of 11.44%, the current average surpasses the previous average price target of $82.50.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive Intra-Cellular Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ami Fadia | Needham | Maintains | Buy | $90.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $90.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $120.00 | - |
| Sumant Kulkarni | Canaccord Genuity | Raises | Buy | $107.00 | $100.00 |
| Ami Fadia | Needham | Raises | Buy | $90.00 | $82.00 |
| Graig Suvannavejh | Mizuho | Raises | Buy | $96.00 | $82.00 |
| Corinne Jenkins | Goldman Sachs | Raises | Neutral | $77.00 | $67.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $91.00 | $82.00 |
| Joel Beatty | Baird | Raises | Outperform | $103.00 | $83.00 |
| Joseph Thome | TD Cowen | Raises | Buy | $90.00 | $80.00 |
| Ami Fadia | Needham | Maintains | Buy | $82.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $82.00 | - |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $86.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $101.00 | - |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $86.00 | - |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $100.00 | $101.00 |
| Ami Fadia | Needham | Raises | Buy | $82.00 | $72.00 |
| Graig Suvannavejh | Mizuho | Raises | Buy | $82.00 | $76.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Intra-Cellular Therapies's stock. This examination reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Intra-Cellular Therapies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Intra-Cellular Therapies analyst ratings.
Delving into Intra-Cellular Therapies's Background
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Intra-Cellular Therapies: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Intra-Cellular Therapies's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 50.41%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -21.73%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Intra-Cellular Therapies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -4.79%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.95%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Intra-Cellular Therapies's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
